Search Results
Your search for The,The matches 34631 pages
Showing 27001 - 27050ASCO Congratulates QOPI-Certified Practices
QCP™: Recognizing Excellence The QOPI® Certification Program (QCP™) recognizes medical oncology and hematology/oncology practices that are committed to delivering the highest quality of cancer care. QCP evaluates an individual practice’s performance in areas that affect patient care and safety. The ...
ASCO International Expands to Improve Cancer Care Worldwide
As a global community of cancer care providers in more than 100 countries around the world, ASCO is uniquely positioned to improve cancer patient outcomes worldwide—an opportunity that it has seized since the organization’s inception through numerous innovative programs. Building upon this...
Expert Point of View: Nasser H. Hanna, MD
In an accompanying editorial, Nasser H. Hanna, MD, of Indiana University, Indianapolis, suggested that although the question of two chemotherapy drugs vs one in this setting made sense at the time GOIRC 02-2006 was initiated, advances in understanding of the heterogeneity of non–small cell lung...
No Benefit of Adding Carboplatin to Pemetrexed in Second-line Treatment of Patients With Advanced Non–Small Cell Lung Cancer
An Italian randomized phase II study (GOIRC 02-2006 study) recently reported in Journal of Clinical Oncology by Andrea Ardizzoni, MD, of Azienda Ospedaliero-Universitaria in Parma, Italy, and colleagues showed no progression-free survival benefit of adding carboplatin to pemetrexed (Alimta) in...
SIDEBAR: Value-based Effective Care
The study by Chen and colleagues addresses the extremely important topic of the use and delivery schedule for radiotherapy in palliation for patients with metastatic lung cancer. The number of patients who will be considered candidates for such therapy in the United States and around the world each ...
Patients Receiving Palliative Radiation Therapy for Metastatic Non–Small Cell Lung Cancer May Be Overtreated
Many patients receiving palliative radiation therapy to the bone or chest for metastatic non–small cell lung cancer (NSCLC) may be receiving a greater number of treatments and higher doses than are supported by current evidence, according to a Cancer Care and Outcomes Research and Surveillance...
Cytarabine in Conditioning Regimen for Younger Patients with MCL
High-dose cytarabine should be incorporated into the induction regimen of younger patients with mantle cell lymphoma (MCL) before autologous stem cell transplantation, according to final results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network, presented at the ASH Annual...
Quizartinib Data Encouraging in Phase II Investigations of FLT3 Mutation–positive Acute Myeloid Leukemia
The investigational oral FLT3 inhibitor quizartinib appears to be a safe and effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML), according to results of a phase II trial presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in...
Expert Point of View: Martin Dreyling, MD
“The BRIGHT study had a noninferiority design, but I question why BR was not found superior, because the StiL trial showed a huge difference in progression-free survival favoring BR,” said Martin Dreyling, MD, Professor at the University of Munich in Germany. “In BRIGHT, BR achieved higher...
Bendamustine/Rituximab Noninferior to Standard Chemotherapy for Advanced Indolent Non-Hodgkin and Mantle Cell Lymphomas
The combination of bendamustine (Treanda) and rituximab (Rituxan), or BR, was found to be noninferior to commonly used chemotherapy with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) in...
Pomalidomide in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On February 8, 2013, the immunomodulatory agent...
Obesity, Physical Inactivity Linked with Risk for Subtype of Colorectal Cancer
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research,1 a journal of the American...
Apogenix Receives FDA Orphan Drug Designation for APG101 to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study
Apogenix GmbH, a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced that its lead compound, APG101 (Apocept), has been granted orphan drug designation from the FDA for the treatment of myelodysplastic syndromes (MDS)....
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from FDA
Janssen Research & Development, LLC, and Pharmacyclics, LLC, announced that the FDA has granted Breakthrough Therapy Designations for the investigational oral agent ibrutinib as a monotherapy for two B-cell malignancies: in patients with relapsed or refractory mantle cell lymphoma who have...
Colorectal Cancer: A Decade of Progress
The 2013 Gastrointestinal Cancers Symposium marked the 10th anniversary of the meeting. Richard M. Goldberg, MD, the Klotz Family Chair in Cancer Research, Professor of Medicine, and James Cancer Hospital Physician-in-Chief at The Ohio State University, looked back over the decade to highlight the...
Expert Point of View: Johanna C. Bendell, MD
The study’s formal discussant, Johanna C. Bendell, MD, Director of Gastrointestinal Cancer Research and at the Sarah Cannon Research Institute, Nashville, said COUGAR02 had “good and appropriate stratification factors” and “importantly, included quality-of-life studies.” This is critical, she said, ...
Second-line Docetaxel Improves Esophageal and Gastric Cancer Survival
A phase III study from the United Kingdom has shown that second-line treatment with docetaxel improves overall survival of patients with advanced esophagogastric cancer.1 The strategy has already been widely adopted, but COUGAR-02 is the first study to provide definitive evidence of a survival...
Expert Point of View: Neal J. Meropol, MD and Johanna C. Bendell, MD
Neal J. Meropol, MD, Chief of Hematology and Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University in Cleveland, commented that the quality of the data on ramucirumab is “very high,” and therefore, “we can believe these results.” The magnitude of the benefit,...
Targeted Therapy Gaining Ground in the Second-line Treatment of Gastric Cancer
In gastric cancer, the concept of targeted therapy assumed clinical significance when the addition of trastuzumab (Herceptin) to chemotherapy improved survival by almost 3 months in the ToGA trial.1 Another anti-HER2 agent, lapatinib (Tykerb), now looks promising, as does an agent targeting the...
Expert Point of View: William K. Oh, MD
Formal discussant William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, Professor of Medicine and Urology, and the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics at Icahn School of Medicine at Mount Sinai, New York, was not convinced that corticosteroids...
Did Corticosteroids Worsen Survival in Patients with Metastatic Prostate Cancer Enrolled in the AFFIRM Trial?
A post hoc analysis of the AFFIRM trial found that on-study use of corticosteroids led to worse outcomes in metastatic castration-resistant prostate cancer regardless of whether patients were randomly assigned to enzalutamide (Xtandi) or placebo.1 On-study corticosteroid use was associated with...
Expert Point of View: William Oh, MD
“The durability of PSA response is encouraging [with ARN-509], as is the toxicity data, but these are relatively asymptomatic patients,” said formal discussant William Oh, MD, Chief of the Division of Hematology and Medical Oncology, Professor of Medicine and Urology, and the Ezra M. Greenspan, MD, ...
Novel Antiandrogen Shows Encouraging Phase II Results in High-risk Nonmetastatic Castrate-resistant Prostate Cancer
Preliminary results of a phase II study suggest that a novel antiandrogen called ARN-509 is safe, well tolerated, and has promising activity in high-risk nonmetastatic castrate-resistant prostate cancer. ARN-509 is a novel, second-generation, oral antiandrogen that binds directly to the...
Expert Point of View: Anthony D’Amico, MD
Now there are mature data from three trials comparing adjuvant radiotherapy vs a wait-and see approach in men following radical prostatectomy, said formal discussant Anthony D’Amico, MD, Dana-Farber Cancer Center and Harvard Medical School, Boston, at the Genitourinary Cancers Symposium. Despite...
Reduced Risk of PSA Failure with Adjuvant Radiotherapy vs Wait-and-see Approach in Stage T3 Prostate Cancer
Extended follow-up of the German ARO 96-02 trial shows that adjuvant radiotherapy reduces the risk of biochemical failure in men whose prostate cancer extends through the prostate capsule (stage T3), compared with a wait-and-see approach, after radical prostatectomy. Adjuvant radiotherapy reduced...
T-DM1 for HER2-positive Metastatic Breast Cancer Receives FDA Approval
The FDA approved the antibodydrug conjugate ado-trastuzumab emtansine (Kadcyla), referred to as T-DM1 during clinical research, for patients with HER2-positive, metastatic breast cancer who were previously treated with trastuzumab (Herceptin) and taxane chemotherapy. Ado-trastuzumab emtansine was...
Cancer Has Made Me A Better Doctor
After six recurrences of colorectal cancer, the chances it will recur again are high. But if I concentrate on that, I couldn’t live my life. In retrospect, I should have paid attention sooner to the abdominal pain I was experiencing and not dismiss it as a simple case of gas. But at age 47 and with ...
Building CancerLinQ: The Road to Faster, More Efficient Treatment Delivery
In June, Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service and Attending Physician at Memorial Sloan-Kettering Cancer Center, and Professor in the Department of Medicine at Weill Cornell Medical College, will begin his term as President of ASCO. Among Dr. Hudis’ priorities will be...
Expert Point of View: Robert A. Wolff, MD and Jordan Berlin, MD
Robert A. Wolff, MD, Professor in the Department of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, Houston, observed, “The bevacizumab seemed to leverage the capecitabine with a magnitude of benefit that is very reminiscent of the initial trials with...
Bevacizumab plus Capecitabine Has Robust Effect in Elderly Patients with Colorectal Cancer
In elderly patients with treatment-naive metastatic colorectal cancer, a trend toward a survival benefit was observed for bevacizumab (Avastin) plus capecitabine (Xeloda) in the international phase III AVEX trial, which was presented at the 2013 Gastrointestinal Cancers Symposium by David...
Thalidomide/Prednisone Maintenance after Stem Cell Transplant Improves Progression-free but Not Overall Survival
Maintenance therapy with thalidomide (Thalomid) and prednisone after autologous stem cell transplantation in patients with multiple myeloma improved progression-free survival but not overall survival, according to results of a phase III trial reported in Blood. Patients receiving maintenance...
Modified and Updated Risk-prediction Model Is More Efficient in Identifying Persons for Lung Cancer Screening
An updated and modified lung-cancer risk-prediction model developed from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial “was more sensitive” for lung cancer detection than criteria from the National Lung Cancer Screening Trial (NLST), according to a study in TheNew...
Two Studies Focus on Treatment Strategies for Preserving the Larynx While Increasing Survival
Two recent studies in the Journal of Clinical Oncology focused on treatment strategies to preserve the larynx while increasing survival of patients with cancer of larynx. RTOG 91-11 Ten-year results from the Radiation Therapy Oncology Group (RTOG) 91-11 trial found that both chemotherapy regimens...
Number of Cancer Survivors Expected to Increase to 18 Million by 2022
The American Association for Cancer Research recently released its second Annual Report on Cancer Survivorship in the United States. The report shows that as of January 2012, there were approximately 13.7 million cancer survivors in the United States, a number that is expected to rise by 31% to 18...
Flaxseed
Dietary supplement use by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
SIDEBAR: SIO’s 10th International Conference
The Society for Integrative Oncology (SIO) will be holding its 10th International Conference in Vancouver, Canada, from Sunday, October 20, 2013 to Tuesday, October 22, 2013. This year’s SIO theme: “From bedside, to bench, to best practices.” The conference will include keynote speakers, plenary...
SIDEBAR: The ‘About Herbs’ Website
The “About Herbs” site (http://www.mskcc.org/cancer-care/integrative-medicine/about-herbs-botanicals-other-products) provides objective information for oncologists and health-care professionals, including a clinical summary for each agent and details about constituents, adverse effects,...
Barrie R. Cassileth, MS, PhD, Champion of Integrative Oncology, Continues to Nurture Growth of the Field
Over the past decade, integrative oncology has gained wide acceptance as an evidenced-based way to improve the lives of patients with cancer throughout the continuum of their care. The ASCO Post recently spoke with Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance ...
Disclosure: Appropriate or Not?
The ASCO Post is an outstanding publication that I always look forward to reading. I also understand there are policies and rules to be followed, particularly regarding conflicts of interest and disclosures from contributors. I am writing in regard to “Cancer Has Made Me A Better Doctor,” by David...
Conflicts of Interest
In looking at a recent issue of The ASCO Post, I noted that expert opinions from specialists were published alongside a number of clinical reports. Below each opinion was a disclosure statement, often saying that the expert had no conflict of interest to report. While I do not know each of these...
Another Perspective on Accountable Care Organizations
I read with great interest Dr. Richard Boxer’s editorial on accountable care organizations in the January 15 issue of The ASCO Post. Much of what he says is unfortunately true. There are several points that I would like to make, however. First of all, Dr. Boxer states that the “principle that...
Alex's Lemonade Stand Foundation Introduces Centers of Excellence Program to Further Childhood Cancer Research
Alex’s Lemonade Stand Foundation (ALSF), a registered 501(c)(3) charity, is furthering its commitment to finding cures for all children with cancer by introducing the ALSF Centers of Excellence program. The Centers of Excellence program aims to fund the research of leading childhood cancer...
Focus on the Louisiana Oncology Society
Founded on September 1, 1992, by John M. Rainey, MD, the Louisiana Oncology Society has had numerous legislative successes (see sidebar) since that time, including leading the effort to support Louisiana’s Oral Chemotherapy Parity Law, which was passed in 2012 and is now in effect throughout the...
Ramon Parsons, MD, PhD, Named Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai
Renowned scientist Ramon E. Parsons, MD, PhD, has been named Chair of the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, New York. Dr. Parsons is a researcher in cancer genetics and will bring an interdisciplinary, holistic approach to Mount Sinai’s research...
Immunoassay Test May Help Identify Early Kidney Cancer
Renal cell carcinoma is the most common form of adult kidney cancer and the third most common urologic malignancy, accounting for about 2% of all malignancies and 2% of cancer-related deaths worldwide. It is also one of the most difficult cancers to detect and treat because it is usually found...
SIDEBAR: Expect Questions from Your Patients
Recently reported data from the Prostate Cancer Outcome Study (PCOS) can “serve as a tool for a medical oncologist, a urologic oncologist, or a radiation oncologist to say, ‘Here is what could happen on average at 2, 5, 15 years after treatment with either surgery or radiation,’” according to the...
Recently Reported Long-term Outcomes Could Motivate More Men with Prostate Cancer to Consider Active Surveillance
Fifteen years after being treated with radical prostatectomy or external-beam radiation for localized prostate cancer, “the prevalence of erectile dysfunction was nearly universal,” among men enrolled in a long-term functional outcomes analysis of the Prostate Cancer Outcomes Study (PCOS). There...
Radiation, Still Misunderstood after All These Years
Over the past few decades, radiation therapies have rapidly advanced, due, in large part, to an increasing technologic armamentarium. Among modern science’s most impressive machines, for example, 220-ton particle accelerators can generate near-light-speed beams of protons, with sniper-like...
New Vice President of Indiana Cancer Services
Holly Goe, RN, MSN, has been named Vice President of Indiana University Health Cancer Centers, Indianapolis. She has been serving as interim Vice President since October after being named the program’s Executive Director for Clinical Operations last April. Before joining IU Health in April 2012,...
Majority of Ovarian Cancer Patients Do Not Receive Recommended Treatment, Study Shows
Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...
